Naloxegol

Naloxegol, also known as and NKTR-118 and AZ-13337019, is a peripherally-selective opioid antagonist for the treatment of opioid-induced constipation. It was approved in 2014 in adult patients with chronic, non-cancer pain. Chemically, naloxegol is a pegylated (polyethylene glycol-modified) derivative of α-naloxol. Specifically, the 5-α-hydroxyl group of α-naloxol is connected via an ether linkage to the free hydroxyl group of a monomethoxy-terminated n=7 oligomer of PEG.

Product information

CAS Number: 854601-70-0

Molecular Weight: 651.78

Formula: C34H53NO11

Synonym:

NKTR-118

NKTR 118

NKTR118

AZ-13337019

AZ13337019

AZ 13337019

EGylated naloxol

Naloxegol Oxalate

trade names Movantik and Moventig

Chemical Name: (1S, 5R, 13R, 14S, 17S)-14-(2, 5, 8, 11, 14, 17, 20-heptaoxadocosan-22-yloxy)-4-(prop-2-en-1-yl)-12-oxa-4-azapentacyclo[9.6.1.0, .0, .0, ]octadeca-7, 9, 11(18)-triene-10, 17-diol

Smiles: COCCOCCOCCOCCOCCOCCOCCO[C@H]1CC[C@@]2(O)[C@H]3CC4=CC=C(O)C5O[C@@H]1[C@]2(CCN3CC=C)C4=5

InChiKey: XNKCCCKFOQNXKV-ZRSCBOBOSA-N

InChi: InChI=1S/C34H53NO11/c1-3-9-35-10-8-33-30-26-4-5-27(36)31(30)46-32(33)28(6-7-34(33,37)29(35)25-26)45-24-23-44-22-21-43-20-19-42-18-17-41-16-15-40-14-13-39-12-11-38-2/h3-5,28-29,32,36-37H,1,6-25H2,2H3/t28-,29+,32-,33-,34+/m0/s1

Technical Data

Appearance: Solid Power.

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: Soluble in DMSO, not in water.

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined.

HS Tariff Code: 382200

References:

1. Chey WD, Webster L, Sostek M, Lappalainen J, Barker PN, Tack J. Naloxegol for opioid-induced constipation in patients with noncancer pain. N Engl J Med. 2014 Jun 19;370(25):2387-96.
2. Daniali M, Nikfar S, Abdollahi M. Evaluating naloxegol for the treatment of opioid-induced constipation. Expert Opin Pharmacother. 2020 Jun;21(8):883-891.

Products are for research use only. Not for human use.